Vanguard Group
TEVA icon

Vanguard Group’s Teva Pharmaceuticals TEVA Stock Holding History

Vanguard Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$28.5M Buy
911,674
+10,688
+1% +$263K ﹤0.01% 2457
2025
Q3 		$18.2M Buy
900,986
+15,540
+2% +$273K ﹤0.01% 2666
2025
Q2 		$14.8M Buy
885,446
+47,814
+6% +$772K ﹤0.01% 2704
2025
Q1 		$12.9M Sell
837,632
-673
-0.1% -$12K ﹤0.01% 2711
2024
Q4 		$18.5M Sell
838,305
-5,883
-0.7% -$107K ﹤0.01% 2624
2024
Q3 		$15.2M Buy
844,188
+17,625
+2% +$308K ﹤0.01% 2738
2024
Q2 		$13.4M Buy
826,563
+1,026
+0.1% +$15.8K ﹤0.01% 2757
2024
Q1 		$11.6M Buy
825,537
+28,071
+4% +$354K ﹤0.01% 2865
2023
Q4 		$8.33M Hold
797,466
– – ﹤0.01% 3055
2023
Q3 		$8.13M Buy
797,466
+28,222
+4% +$263K ﹤0.01% 2999
2023
Q2 		$5.79M Hold
769,244
– – ﹤0.01% 3237
2023
Q1 		$6.81M Sell
769,244
-820
-0.1% -$8.11K ﹤0.01% 3159
2022
Q4 		$7.02M Hold
770,064
– – ﹤0.01% 3129
2022
Q3 		$6.21M Buy
770,064
+13,786
+2% +$122K ﹤0.01% 3210
2022
Q2 		$5.69M Buy
756,278
+61,842
+9% +$539K ﹤0.01% 3310
2022
Q1 		$6.52M Sell
694,436
-11,352
-2% -$94.7K ﹤0.01% 3384
2021
Q4 		$5.65M Sell
705,788
-155,469
-18% -$1.4M ﹤0.01% 3537
2021
Q3 		$8.39M Buy
861,257
+15,562
+2% +$146K ﹤0.01% 3354
2021
Q2 		$8.37M Sell
845,695
-264,687
-24% -$2.8M ﹤0.01% 3304
2021
Q1 		$12.8M Buy
1,110,382
+15,634
+1% +$179K ﹤0.01% 3017
2020
Q4 		$10.6M Sell
1,094,748
-127,826
-10% -$1.22M ﹤0.01% 2964
2020
Q3 		$11M Sell
1,222,574
-183,547
-13% -$1.94M ﹤0.01% 2740
2020
Q2 		$17.3M Sell
1,406,121
-189,439
-12% -$2.14M ﹤0.01% 2491
2020
Q1 		$14.3M Sell
1,595,560
-141,781
-8% -$1.45M ﹤0.01% 2442
2019
Q4 		$17M Sell
1,737,341
-92,358
-5% -$825K ﹤0.01% 2608
2019
Q3 		$12.6M Sell
1,829,699
-190,871
-9% -$1.46M ﹤0.01% 2708
2019
Q2 		$18.6M Buy
2,020,570
+126,139
+7% +$1.52M ﹤0.01% 2539
2019
Q1 		$29.7M Sell
1,894,431
-62,585
-3% -$1.1M ﹤0.01% 2328
2018
Q4 		$30.2M Sell
1,957,016
-87,630
-4% -$1.8M ﹤0.01% 2260
2018
Q3 		$44M Sell
2,044,646
-2,908
-0.1% -$67.5K ﹤0.01% 2209
2018
Q2 		$49.8M Buy
2,047,554
+120,755
+6% +$2.46M ﹤0.01% 2129
2018
Q1 		$32.9M Buy
1,926,799
+207,997
+12% +$4.06M ﹤0.01% 2290
2017
Q4 		$32.6M Buy
1,718,802
+65,213
+4% +$981K ﹤0.01% 2292
2017
Q3 		$29.1M Sell
1,653,589
-144,762
-8% -$3.26M ﹤0.01% 2316
2017
Q2 		$59.7M Sell
1,798,351
-4,281
-0.2% -$133K ﹤0.01% 1931
2017
Q1 		$57.8M Sell
1,802,632
-47,169
-3% -$1.61M ﹤0.01% 1934
2016
Q4 		$67.1M Buy
1,849,801
+1,348,238
+269% +$53.8M ﹤0.01% 1836
2016
Q3 		$23.1M Sell
501,563
-1,300
-0.3% -$67.8K ﹤0.01% 2299
2016
Q2 		$25.3M Buy
502,863
+556
+0.1% +$29.6K ﹤0.01% 2228
2016
Q1 		$26.9M Sell
502,307
-3,678
-0.7% -$216K ﹤0.01% 2161
2015
Q4 		$33.2M Buy
505,985
+399,164
+374% +$24.7M ﹤0.01% 2083
2015
Q3 		$6.03M Buy
106,821
+141
+0.1% +$9.14K ﹤0.01% 2882
2015
Q2 		$6.3M Buy
106,680
+98,430
+1,193% +$6.07M ﹤0.01% 2899
2015
Q1 		$514K Buy
+8,250
New +$480K ﹤0.01% 3823

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Group's TEVA Position: Q4 2025 in Review

Vanguard Group increased its Teva Pharmaceuticals (TEVA) stake by 1.2% in Q4 2025, buying an estimated $263K and bringing the position to 911,674 shares worth $28.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2457.

Vanguard Group first reported a position in TEVA in Q1 2015 and has held it in 44 quarters since. The position peaked at $67.1M in Q4 2016. 631 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • Vanguard Group held 911,674 shares of Teva Pharmaceuticals worth $28.5M as of Q4 2025.
  • Vanguard Group bought 10,688 Teva Pharmaceuticals shares in Q4 2025, an estimated $263K.
  • Teva Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2457 holding.
  • Vanguard Group first reported a position in Teva Pharmaceuticals in Q1 2015 and has held it in 44 quarters since.
  • Vanguard Group's Teva Pharmaceuticals position peaked at $67.1M in Q4 2016.
  • 631 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.